Investing.com - Boston Scientific (NYSE: BSX) reported third quarter EPS of $0.50, $0.02 better than the analyst estimate of $0.48. Revenue for the quarter came in at $3.53B versus the consensus estimate of $3.48B.
Guidance
Boston Scientific sees Q4 2023 EPS of $0.49-$0.52 versus the analyst consensus of $0.52.
Boston Scientific sees FY 2023 EPS of $1.99-$2.02 versus the analyst consensus of $2.00.
Boston Scientific's stock price closed at $49.99. It is down -3.29% in the last 3 months and up 20.23% in the last 12 months.
Boston Scientific saw 3 positive EPS revisions and 13 negative EPS revisions in the last 90 days. See Boston Scientific's stock price’s past reactions to earnings here.
According to InvestingPro, Boston Scientific's Financial Health score is "great performance".
Check out Boston Scientific's recent earnings performance, and Boston Scientific's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar